Compare D Wave Quantum Inc (QBTS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs ResMed Inc. — how do they compare? D Wave Quantum Inc trades at $14.52 (market cap $5.54B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 5.8× D Wave Quantum Inc's market cap, and ResMed Inc. pays a 1.16% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D Wave Quantum Inc for 32 Days and ResMed Inc. for 51 Days on average.
| QBTS | RMD | |
|---|---|---|
Market Cap | $5.54B | $31.89B |
Volume | 16,671,452 | 618,314 |
Sector | Technology | Health |
52-Week High | $44.78 | $277.88 |
52-Week Low | $12.98 | $182.82 |
Typical Hold Time | 32 Days | 51 Days |
Enterprise Value | $5.04B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D-Wave Quantum (QBTS) trades at $14.57, down 4.27% today, amid ongoing legal investigations and negative earnings trends. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal severe losses with a -2,001.59% net income margin despite 64.19% gross margins. Recent quarterly earnings have been mixed, missing expectations in two of the last three reported quarters.
Despite unanimous analyst buy ratings and a $34.38 price target suggesting 136% upside, significant execution risks persist. The company faces cash burn challenges with negative operating cash flow and relies heavily on financing activities. Legal investigations and competitive pressures in the quantum computing sector create substantial uncertainty for investors.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
